Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
NASDAQ:FATE
Price:
4.23 USD
1.93%
Market Closed
Updated:
May 14, 2024
P/E
Price to Earnings
Price to Earnings
-3
Current
-8.1
Median
27.4
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-3
Market Cap
/
481.3m
Net Income
-160.9m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Fate Therapeutics Inc
NASDAQ:FATE
|
481.3m USD | -3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.2B USD | 58.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
165.9B USD | 44.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 30.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108B USD | 28 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 36.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.8B USD | 173.5 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
48.6B USD | -8.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.7B USD | 28.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 73.8 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-2.1
2-Years Forward
P/E
-2.3
3-Years Forward
P/E
-2.4
You don't have any saved screeners yet
